(Reuters) - Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously ...

The board of directors of (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on December 10, 2024, to ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2025, according to Statista. A large portion of that figure is from the oncology segment, which is expected ...

These blue chip dividend stocks would be ideal for investors who had to hold them forever. They provide reliable streams of ...

Future Financial Wealth Managment LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in ...

Peddock Capital Advisors LLC lowered its position in Mastercard Incorporated (NYSE:MA – Free Report) by 1.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The ...

BMO chief investment strategist Brian Belski provided an update on his popular North American Dividend Growth portfolio, ...

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often ...

Discover why Gilead Sciences is a strong buy with potential blockbuster drugs in HIV and oncology, favorable valuation, and a ...

On the other hand, Gilead Sciences' revenue is growing nicely, at a compound rate of 4.8% over the last five years. It's ...

The long-term potential for dividend growth is even higher, thanks to ongoing share repurchases. Patient investors interested in dividends should consider this stock over the competition.